Miranda R Yourick
Overview
Explore the profile of Miranda R Yourick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campasino K, Yourick M, Zhao Y, Sepehr E, Vaught C, Yourick J, et al.
Toxicol In Vitro
. 2024 Sep;
101:105933.
PMID: 39233107
Since the passage of the 2018 Agriculture Improvement Act (2018 Farm Bill), the number of products containing cannabis-derived compounds available to consumers have rapidly increased. Potential effects on liver function...
2.
Gao X, Campasino K, Yourick M, Zhao Y, Sepehr E, Vaught C, et al.
Toxicology
. 2024 Jul;
506:153885.
PMID: 39004335
Cannabidiol (CBD) has been reported to induce hepatotoxicity in clinical trials and research studies; however, little is known about the safety of other nonintoxicating cannabinoids. New approach methodologies (NAMs) based...
3.
Gao X, Johnson W, Yourick M, Campasino K, Sprando R, Yourick J
Regul Toxicol Pharmacol
. 2024 Jun;
151:105653.
PMID: 38825064
Despite two decades of research on silver nanoparticle (AgNP) toxicity, a safe threshold for exposure has not yet been established, albeit being critically needed for risk assessment and regulatory decision-making....
4.
Gao X, Campasino K, Yourick M, Cao Y, Yourick J, Sprando R
J Appl Toxicol
. 2024 May;
44(9):1329-1346.
PMID: 38724177
Dietary supplements containing usnic acid have been increasingly marketed for weight loss over the past decades, even though incidences of severe hepatotoxicity and acute liver failure due to their overuse...
5.
Carleton K, Yourick M
Semin Cell Dev Biol
. 2020 May;
106:43-52.
PMID: 32439270
The family Cichlidae contains approximately 2000 species that live in diverse freshwater habitats including murky lakes, turbid rivers, and clear lakes from both the Old and New Worlds. Their visual...
6.
Buser A, Lindhurst M, Kondolf H, Yourick M, Keppler-Noreuil K, Sapp J, et al.
Cold Spring Harb Mol Case Stud
. 2020 Apr;
6(3).
PMID: 32327430
Proteus syndrome is a mosaic disorder that can cause progressive postnatal overgrowth of nearly any organ or tissue. To date, Proteus syndrome has been exclusively associated with the mosaic c.49G...
7.
Yourick M, Sandkam B, Gammerdinger W, Escobar-Camacho D, Nandamuri S, Clark F, et al.
Mol Ecol Resour
. 2019 Jul;
19(6):1447-1460.
PMID: 31325910
To determine the visual sensitivities of an organism of interest, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) is often used to quantify expression of the light-sensitive opsins in the retina. While...
8.
Lindhurst M, Brinster L, Kondolf H, Shwetar J, Yourick M, Shiferaw H, et al.
Hum Mol Genet
. 2019 Jun;
28(17):2920-2936.
PMID: 31194862
Proteus syndrome is a mosaic, progressive overgrowth disorder caused by a somatic activating variant c.49G > A p.(E17K) in AKT1. The presentation in affected individuals is variable, with a diversity...
9.
Nandamuri S, Yourick M, Carleton K
Mol Ecol
. 2017 Sep;
26(21):6036-6052.
PMID: 28926160
Phenotypic plasticity allows organisms to adapt quickly to local environmental conditions and could facilitate adaptive radiations. Cichlids have recently undergone an adaptive radiation in Lake Malawi where they inhabit diverse...
10.
Lindhurst M, Yourick M, Yu Y, Savage R, Ferrari D, Biesecker L
Sci Rep
. 2015 Dec;
5:17162.
PMID: 26657992
A somatic activating mutation in AKT1, c.49G>A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome. ARQ 092 is an...